AGM/EGM15 Jun 2026, 09:20 pm
Corona Remedies FY26 Annual Report & AGM Notice Issued
AI Summary
Corona Remedies Ltd has released its Annual Report for FY 2025-26, coinciding with the notice for its 22nd Annual General Meeting (AGM) scheduled for July 9, 2026. The report highlights a landmark year with India business revenue growth of 17.18%, significantly outperforming the IPM growth of 8.59%. Key financial metrics include Revenue from Operations at ₹1,403.18 Crores, Operating Profit at ₹293.44 Crores, and PAT at ₹199.42 Crores. The company also announced July 2, 2026, as the cut-off date for electronic voting and AGM attendance. The report details strategic expansions, new product launches, and strengthening of its specialty-led field structure.
Key Highlights
- FY26 India business revenue grew 17.18%, outperforming IPM growth by 859 bps.
- Revenue from Operations reached ₹1,403.18 Cr; PAT stood at ₹199.42 Cr.
- AGM scheduled for July 9, 2026, with July 2 as the cut-off date for voting.
- Company acquired 8 brand trademarks and expanded into biosimilars.
- Manufacturing capacity enhanced with Gujarat facility scale-up.
Price Impact
More from CORONA